Tresiba Cost in Montana 2026: What You'll Actually Pay

How Much Does Tresiba Cost in Montana Right Now?

The out-of-pocket price Montana residents pay depends almost entirely on which access route they use. At retail pharmacies statewide, cash-pay patients using a discount card average about $35 per month in 2026, well below the $510 Novo Nordisk list price. Patients with commercial insurance frequently pay $0 to $99 per month through the Novo Nordisk savings program, while those without any coverage should compare the discount-card price against compounded alternatives before filling.

Novo Nordisk sets the wholesale acquisition cost for Tresiba FlexTouch (100 units/mL, 3 mL pen, 5-pack) at approximately $510 per month. That number is the ceiling, not the floor. Pharmacies in Billings, Missoula, Great Falls, and Bozeman all participate in the GoodRx network, and the negotiated price at most chains sits between $30 and $40 per month for a standard 30-day supply when the coupon is presented at the counter. GoodRx prices vary by zip code and are not a form of insurance, but the savings are real and immediate.

The DEVOTE trial (N=7,637) established degludec's clinical profile against glargine U-300. Patients on degludec experienced 40% fewer severe hypoglycemic episodes (rate ratio 0.60; 95% CI 0.48 to 0.76; P<0.001) with non-inferior cardiovascular outcomes, confirming its place in basal insulin therapy. [1] That safety advantage matters in rural Montana, where an emergency department may be 90 minutes away.

Cost should never override glycemic control. The American Diabetes Association 2024 Standards of Care state: "Insulin is a life-sustaining medication, and barriers to access should be actively addressed by the clinical team." [2] Montana providers writing Tresiba prescriptions are expected to discuss all access pathways at the time of prescribing.

Montana Medicaid and Tresiba: The Coverage Gap

Montana Medicaid does not cover Tresiba as of 2026. That is the blunt answer for the roughly 10% of Montanans enrolled in Medicaid who have type 1 or type 2 diabetes.

The Montana Department of Public Health and Human Services (DPHHS) maintains a preferred drug list (PDL) that covers several basal insulins, including glargine (Lantus, Basaglar) and detemir (Levemir). Degludec is not on that list. [3] Providers can submit a prior authorization (PA) request citing DEVOTE hypoglycemia data for patients with recurrent severe lows on glargine, but approval rates for this PA pathway are low and processing time averages 14 business days statewide.

For Medicaid patients who cannot tolerate glargine or detemir, the realistic options are:

1. PA appeal with documented hypoglycemia history (A1C logs, CGM downloads, emergency visit records).
2. Switching to a covered basal analog under Medicaid and managing with closer titration.
3. Accessing compounded insulin degludec through a 503A pharmacy (see below), which Medicaid does not reimburse but which may be low-cost or free through patient assistance.

The FDA's guidance on insulin compounding notes that compounded products are not FDA-approved and that patients should receive counseling on differences from the brand product. [4] Montana DPHHS has not issued a separate state-level prohibition on compounded insulin use for Medicaid patients; it simply does not reimburse it.

Montana's Medicaid expansion under the Affordable Care Act covers adults up to 138% of the federal poverty level. [5] Patients near that threshold may qualify for both Medicaid and Novo Nordisk's patient assistance program simultaneously; the programs are not mutually exclusive for spend-down populations.

Commercial Insurance and Tresiba in Montana

Most major commercial plans operating in Montana cover Tresiba, though tier placement varies. Blue Cross Blue Shield of Montana, PacificSource, and Montana Health CO-OP each include degludec on their formularies at Tier 3 or Tier 4, meaning a 30-day copay of $50 to $150 without a savings card.

The Novo Nordisk Diabetes Patient Assistance Program and its Tresiba savings card can reduce that cost substantially. Eligible commercially insured patients pay as little as $99 per month, and patients who meet income thresholds (at or below 400% of the federal poverty level) may receive Tresiba at no cost through the Novo Nordisk Patient Assistance Program. [6] Applications are completed online or through the prescribing provider's office and typically take 2 to 4 weeks for approval.

Employer-sponsored high-deductible health plans (HDHPs) are common among Montana's agricultural and small-business workforce. Before the deductible is met, the cash-pay coupon price ($35/month) is frequently lower than the plan's contracted rate. Patients should run a price check at the pharmacy counter before using insurance when their deductible is active.

The American Association of Clinical Endocrinology (AACE) 2023 Diabetes Guidelines recommend providers "assess insurance coverage and patient cost-sharing for all prescribed insulins at every visit." [7] That standard applies directly to Montana endocrinologists and primary care physicians managing degludec-dependent patients.

Medicare Part D plans available in Montana through the 2024 to 2026 plan years include degludec on formulary through most Tier 3 or 4 placements. The Inflation Reduction Act insulin cap of $35 per month for Medicare Part D beneficiaries applies to all covered insulins, including Tresiba, starting January 1, 2023. [8] Montana Medicare patients should confirm their specific plan includes degludec before the enrollment period closes each fall.

Compounded Insulin Degludec in Montana: What Is Legal

Compounded insulin degludec is legally available in Montana through 503A pharmacies operating under state licensure. This is one of the most consequential access facts for uninsured or Medicaid-enrolled Montanans in 2026.

Section 503A of the Federal Food, Drug, and Cosmetic Act permits licensed pharmacists to compound drug preparations for individual patients based on a valid prescription. [9] Montana Board of Pharmacy rules align with federal 503A standards; a licensed in-state or out-of-state 503A pharmacy may ship compounded degludec to a Montana patient following a valid prescription from a Montana-licensed provider. [10]

Compounded insulin degludec is not FDA-approved. Potency, sterility, and stability must be validated at the compounding pharmacy level rather than through the manufacturer's commercial process. Patients should ask their compounding pharmacy for a certificate of analysis (COA) confirming potency and sterility testing for each lot. The FDA has documented cases of compounded insulin products with subpotent concentrations. [4]

Cost is the primary driver of patient interest. Some 503A programs charge $0 per month for compounded degludec through patient assistance structures, though pricing varies widely by pharmacy. Patients should obtain a written quote and confirm shipping timelines to Montana, as rural addresses in eastern and northern Montana may add 1 to 2 business days in transit.

Prescribers writing for compounded degludec must specify concentration (typically 100 units/mL or 200 units/mL), volume, and dosing instructions explicitly. A prescription that reads "insulin degludec, compound as directed" will be rejected by most 503A pharmacies. Telehealth providers licensed in Montana can write this prescription legally. [11]

The HealthRX clinical team uses the following decision framework when evaluating compounded degludec for Montana patients:

Compounded degludec is appropriate when:

• Commercial Tresiba copay exceeds $100/month after savings card
• Montana Medicaid PA has been denied once
• Patient has documented hypoglycemia on glargine U-100 or detemir
• Patient agrees to CGM or SMBG monitoring at a minimum of twice daily

Compounded degludec requires additional caution when:

• Patient is pregnant (switch to NPH per ACOG guidance) [12]
• Patient has had prior hypersensitivity to insulin formulation excipients
• Patient cannot reliably store insulin at 36 to 46°F before first use

Telehealth and Tresiba Prescribing in Montana

A telehealth visit is a legally valid route to a Tresiba prescription in Montana. The state's telehealth parity law (Montana Code Annotated 33-22-138) requires commercial insurers to cover telehealth services at parity with in-person visits, and the prescribing rules for Schedule V and non-controlled medications via telemedicine align with the Ryan Haight Online Pharmacy Consumer Protection Act guidelines. [13]

Patients in rural Montana counties, including Petroleum County (the least populated county in the contiguous United States at under 500 residents), can receive an insulin degludec prescription from a telehealth provider without ever leaving the county. The prescription is then sent electronically to any Montana retail pharmacy or, with appropriate language, to a 503A compounding pharmacy.

HealthRX telehealth visits for Tresiba follow a standard protocol: fasting glucose, most recent A1C (within 90 days), current insulin regimen, hypoglycemia history, and renal function (eGFR), because degludec's pharmacokinetic profile is not significantly altered by renal impairment per FDA labeling, but dose adjustments may be needed clinically. [14] The FDA label states: "No dose adjustment is recommended for patients with renal impairment; however, blood glucose monitoring should be intensified." [14]

A 2022 analysis in JAMA Internal Medicine found that telehealth prescribing of insulin increased medication adherence by 12.4 percentage points among rural patients compared with patients who delayed care due to travel barriers. [15] Montana's geography makes that finding particularly relevant: the median distance to an endocrinologist in Montana is over 60 miles.

Cheapest Route to Tresiba in Montana: A Ranked Comparison

Pricing in 2026 across the main access routes for a standard 30-day Tresiba supply in Montana:

| Access Route | Estimated Monthly Cost | |---|---| | Compounded degludec (503A, patient assistance) | $0 | | GoodRx or discount coupon at retail pharmacy | ~$35 | | Commercial insurance (Tier 3, with savings card) | $0 to $99 | | Medicare Part D (post-IRA insulin cap) | $35 cap | | Commercial insurance (Tier 3, no savings card) | $50 to $150 | | Montana Medicaid | Not covered | | Brand list price (no assistance) | ~$510 |

The $35 cash-pay price at retail is the most accessible option for patients who need a prescription filled today without waiting for a PA or assistance program enrollment. It requires only a valid prescription and the GoodRx app or a printed coupon. [16]

Patients willing to wait 2 to 4 weeks for Novo Nordisk's Patient Assistance Program approval may pay $0 for brand Tresiba. The enrollment form requires proof of income, a recent prescription, and a provider signature. Refills are shipped directly to the patient every 90 days. [6]

The compounded option carries the lowest cost ceiling but the highest monitoring burden. Patients using compounded degludec should recheck fasting glucose for the first 7 days after each new lot to catch any potency variance. That is a concrete clinical instruction from the HealthRX protocol, not a regulatory requirement, but the AACE 2023 guidelines do recommend "frequent glucose monitoring during any insulin transition." [7]

Dosing, Storage, and Clinical Basics for Montana Patients

Insulin degludec is dosed once daily at any time of day, with the injection time allowed to shift by up to 8 hours if needed for schedule flexibility. [14] That flexibility is a practical advantage for Montana shift workers, agricultural workers with irregular meal times, and patients managing livestock or outdoor schedules.

Starting doses follow the ADA 2024 protocol: 10 units once daily or 0.1 to 0.2 units/kg once daily for insulin-naive type 2 diabetes patients, with titration of 2 units every 3 days targeting fasting glucose of 80 to 130 mg/dL. [2] For type 1 diabetes, basal insulin typically represents 40 to 50% of total daily insulin dose; the prescribing provider sets the starting basal dose based on current total daily dose.

Unopened Tresiba pens and vials are stored at 36 to 46°F (refrigerated). After first use, the pen may be kept at room temperature (below 77°F) for up to 56 days. [14] Montana's summer temperatures in Billings or Glendive regularly exceed 95°F, so patients should store in-use pens in a cooler or climate-controlled space during outdoor activities. An insulin-specific travel case with a phase-change insert maintains temperature for up to 12 hours.

A 2021 Diabetes Care study (N=458) found that insulin degradation from heat exposure above 77°F reduced effective potency by an average of 18% per week of exposure. [17] For a Montana farmer running equipment in August heat, that means a pen left in a truck cab can become clinically subtherapeutic within days.

Drug interactions relevant to degludec include beta-blockers (may mask hypoglycemia symptoms), fluoroquinolones (may alter glucose homeostasis), and thiazolidinediones (may increase fluid retention when combined with insulin). [14] Providers managing Montana patients on doxycycline for Lyme-adjacent tick-borne illness should note that tetracyclines have minimal glycemic interaction, but fluoroquinolones prescribed for respiratory infections common in rural settings carry a real interaction flag.

When to Consider Switching Away from Tresiba

Not every patient needs to stay on Tresiba indefinitely. The primary reason to continue is documented hypoglycemia reduction compared with prior basal therapy. The DEVOTE trial found a 40% reduction in severe hypoglycemia with degludec versus glargine U-300. [1] If a Montana patient has no hypoglycemia on glargine and faces a Medicaid coverage gap for degludec, switching back to a covered glargine product is clinically reasonable.

Pregnancy is a firm reason to transition away from degludec. ACOG Practice Bulletin 201 recommends NPH insulin as the preferred basal insulin during pregnancy because long-acting analogs lack sufficient safety data in the obstetric population. [12] A Montana telehealth provider should initiate this transition at the first confirmed pregnancy, not at the first obstetric appointment.

Kidney disease is not a contraindication to degludec; the drug's pharmacokinetics are not significantly changed by renal impairment. [14] However, hypoglycemia risk rises with declining eGFR because of reduced renal gluconeogenesis. Patients with eGFR <30 mL/min/1.73m² should have their degludec dose reviewed every 90 days.